Cinqair (reslizumab) - Merck (MSD), UCB, Teva
Xolair (omalizumab) - Roche, Novartis
Nucala (mepolizumab) - GSK
Fasenra (benralizumab) - AstraZeneca
Dupixent (dupilumab) - Sanofi, Regeneron
http://www.ncbi.nlm.nih.gov/pubmed/39479509
 
; Alan Altraja; Anna Quinton; Arnaud Bourdin; Bassam Mahboub; Bill Cook; Celine Bergeron; Chin Kook Rhee; Clement Erhard; David B Price; George C Christoff; Lauri Lehtimäki; Luis Pérez-de-Llano; Mariko Siyue Koh; Neil Martin; Nikolaos G Papadopoulos; Paul Pfeffer; Rohit Katial; Tham T Le; Trung N Tran; Victoria Carter
 
Oct 31, 2024
 
Next